AR080313A1 - Composiciones de virus de moquillo canino (cdv) recombinante y sus usos - Google Patents

Composiciones de virus de moquillo canino (cdv) recombinante y sus usos

Info

Publication number
AR080313A1
AR080313A1 ARP110100587A ARP110100587A AR080313A1 AR 080313 A1 AR080313 A1 AR 080313A1 AR P110100587 A ARP110100587 A AR P110100587A AR P110100587 A ARP110100587 A AR P110100587A AR 080313 A1 AR080313 A1 AR 080313A1
Authority
AR
Argentina
Prior art keywords
cdv
compositions
recombinant canine
methods
canine
Prior art date
Application number
ARP110100587A
Other languages
English (en)
Inventor
Jules Minke
Jean-Christophe Audonnet
Original Assignee
Merial Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Ltd filed Critical Merial Ltd
Publication of AR080313A1 publication Critical patent/AR080313A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/175—Canine distemper virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18471—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Vectores que contienen y expresan, in vivo o in vitro, polipéptidos o antígenos CDV que generan una respuesta inmune en animales contra el CDV, composiciones que comprenden dichos vectores y/o polipéptidos CDV, y métodos de vacunacion contra el CDV. La invencion provee además métodos para inducir una respuesta inmunogénica o protectora contra CDV y otros virus caninos, así como métodos para prevenir o tratar el CDV y otros virus caninos o estados de enfermedad causados por el CDV y otros virus caninos.
ARP110100587A 2010-02-26 2011-02-25 Composiciones de virus de moquillo canino (cdv) recombinante y sus usos AR080313A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30862010P 2010-02-26 2010-02-26

Publications (1)

Publication Number Publication Date
AR080313A1 true AR080313A1 (es) 2012-03-28

Family

ID=44022809

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110100587A AR080313A1 (es) 2010-02-26 2011-02-25 Composiciones de virus de moquillo canino (cdv) recombinante y sus usos

Country Status (24)

Country Link
US (3) US20130197612A1 (es)
EP (1) EP2538972B1 (es)
JP (1) JP5898632B2 (es)
KR (1) KR20130036209A (es)
CN (1) CN102971010A (es)
AR (1) AR080313A1 (es)
AU (1) AU2011220410B9 (es)
BR (1) BR112012021545B1 (es)
CA (1) CA2791787C (es)
CY (1) CY1120430T1 (es)
DK (1) DK2538972T3 (es)
ES (1) ES2676542T3 (es)
HR (1) HRP20181188T1 (es)
HU (1) HUE039735T2 (es)
LT (1) LT2538972T (es)
NZ (1) NZ602077A (es)
PL (1) PL2538972T3 (es)
PT (1) PT2538972T (es)
RS (1) RS57759B1 (es)
RU (1) RU2567337C2 (es)
SI (1) SI2538972T1 (es)
SM (1) SMT201800310T1 (es)
WO (1) WO2011106743A1 (es)
ZA (1) ZA201206209B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103525776A (zh) * 2013-10-23 2014-01-22 华中农业大学 一种重组狂犬病病毒口服疫苗株及其制备方法
CN104164409A (zh) * 2014-07-18 2014-11-26 中国人民解放军军事医学科学院军事兽医研究所 含有犬gmcsf基因的重组犬瘟热病毒及其制备方法
US10081796B2 (en) * 2015-01-12 2018-09-25 International Aids Vaccine Initiative Neutralization-resistant CDV mutants and viral vectors
UY37405A (es) 2016-09-20 2018-03-23 Boehringer Ingelheim Vetmedica Gmbh Vectores de adenovirus canino
AR109539A1 (es) 2016-09-20 2018-12-19 Boehringer Ingelheim Vetmedica Gmbh Sitio de inserción orf70 de ehv
WO2018054840A1 (en) 2016-09-20 2018-03-29 Boehringer Ingelheim Vetmedica Gmbh New promoters
US10626414B2 (en) 2016-09-20 2020-04-21 Boehringer Ingelheim Vetmedica Gmbh Swine influenza vaccine
CN109265522B (zh) * 2018-09-29 2022-03-04 东北农业大学 用于检测犬瘟热病毒血凝蛋白h抗体的致敏聚苯乙烯纳米微球及其制备方法和应用
WO2020086939A1 (en) * 2018-10-26 2020-04-30 The Wistar Institute Of Anatomy And Biology Canine distemper vaccines and methods of treatment using the same
RU2768749C1 (ru) * 2021-06-07 2022-03-24 Федеральное государственное бюджетное учреждение "Федеральный центр охраны здоровья животных" (ФГБУ "ВНИИЗЖ") Средство специфической профилактики covid-19 для плотоядных животных
CN114480441B (zh) * 2021-12-21 2023-03-21 长春维石检测技术服务有限公司 一段核苷酸序列及其表达重组蛋白纳米颗粒在犬瘟热病毒疫苗的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US702919A (en) * 1902-02-03 1902-06-24 Adam Simpson Boyd Pipe cutter and wrench.
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
KR920701252A (ko) 1989-10-10 1992-08-11 스티븐 엠. 오드레 과립구 군체 자극인자 및 그를 이용하여 개 및 고양이과 동물의 전염병을 치료하거나 예방하는 방법
US5756102A (en) 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US6309647B1 (en) * 1999-07-15 2001-10-30 Aventis Pasteur Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants
CA2044468C (en) 1990-11-21 2006-08-22 Richard A. Nash Canine granulocyte macrophage colony stimulating factor
ATE247163T1 (de) 1991-03-07 2003-08-15 Virogenetics Corp Gentechnologisch hergestellter stamm für impfstoffe
CN1117081A (zh) * 1995-03-16 1996-02-21 高云 犬瘟热狂犬病细小病毒三联活疫苗、毒种及制造方法
EP0826063A1 (en) 1995-04-25 1998-03-04 Vical Incorporated Single-vial formulations of dna/lipid complexes
US20010036928A1 (en) * 1996-04-22 2001-11-01 Chamberlain Ronald S. Heterologous boosting immunizations
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
FR2750865B1 (fr) * 1996-06-27 1998-12-04 Rhone Merieux Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2
WO1998000166A1 (en) * 1996-07-03 1998-01-08 Merial, Inc. Recombinant canine adenovirus (cav) containing exogenous dna
FR2751228B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Vaccin polynucleotidique bovin pour voie intradermique
FR2751225B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
US7294338B2 (en) 1996-07-19 2007-11-13 Merial Polynucleotide vaccine formula against canine pathologies, in particular respiratory and digestive pathologies
FR2751226B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
FR2751224B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
FR2751229B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
US6610661B1 (en) 1996-10-11 2003-08-26 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
BR9712852A (pt) * 1996-10-23 1999-11-16 Univ Pennsylvania Plasmìdeo, composição, processo de imunização de um indivìduo contra um patógeno, vacina recombinante, patógeno vivo atenuado, proteìna bl-1 substancialmente pura, vetor recombinante de expressão, e, anticorpo isolado
JP2002507985A (ja) 1997-06-30 2002-03-12 ローヌ−プーラン・ロレ・エス・アー 横紋筋に核酸を導入する改良法およびその組合せ
FR2775601B1 (fr) * 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
FR2778858B1 (fr) 1998-05-20 2000-06-16 Oreal Emulsion e/h/e stable et son utilisation comme composition cosmetique et/ou dermatologique
US6645740B1 (en) 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
AU782154C (en) * 1999-06-10 2006-02-09 Boehringer Ingelheim Animal Health USA Inc. DNA vaccines for pets and sport animals
FR2794648B1 (fr) * 1999-06-10 2003-03-07 Merial Sas Vaccins adn pour animaux de compagnie et de sport
FR2801607B1 (fr) 1999-11-26 2001-12-28 Merial Sas Pneumovirus du canard et vaccins correspondants
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
WO2002020937A1 (en) 2000-09-06 2002-03-14 The Charles Machine Works, Inc. Auxiliary pipe loading device
US7740863B2 (en) * 2001-04-06 2010-06-22 Merial Recombinant vaccine against West Nile Virus
AU2003281917A1 (en) 2002-09-23 2004-04-19 Mologen Ag Vaccine against infections caused by oncoviruses such as the feline leucosis virus of cats
CA2533581C (en) 2003-07-24 2012-05-08 Merial Limited Vaccine formulations comprising an oil-in-water emulsion
JP5060284B2 (ja) 2004-03-30 2012-10-31 アンスティテュ・グスターブ・ルシ ウイルスタンパク質の免疫抑制作用のモデュレーションに関与するポリペプチド配列
WO2008036061A2 (en) * 2005-04-06 2008-03-27 Verenium Corporation Enzymes and formulations for broad-specificity decontamination of chemical and biological warfare agents
US7682619B2 (en) * 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
CN105535961A (zh) * 2008-04-04 2016-05-04 宾夕法尼亚大学托管会 使用il-28和组合物的疫苗和免疫治疗及其使用方法

Also Published As

Publication number Publication date
RU2012140741A (ru) 2014-04-10
ZA201206209B (en) 2013-06-26
PT2538972T (pt) 2018-07-30
US20130197612A1 (en) 2013-08-01
AU2011220410B9 (en) 2015-07-30
AU2011220410A1 (en) 2012-09-20
SMT201800310T1 (it) 2018-07-17
EP2538972A1 (en) 2013-01-02
CY1120430T1 (el) 2019-07-10
DK2538972T3 (en) 2018-07-30
US10076566B2 (en) 2018-09-18
HUE039735T2 (hu) 2019-01-28
WO2011106743A1 (en) 2011-09-01
US20110236419A1 (en) 2011-09-29
CA2791787A1 (en) 2011-09-01
US20160199483A1 (en) 2016-07-14
JP5898632B2 (ja) 2016-04-06
BR112012021545A2 (pt) 2018-09-04
LT2538972T (lt) 2018-07-25
US9327137B2 (en) 2016-05-03
BR112012021545B1 (pt) 2020-11-03
HRP20181188T1 (hr) 2018-10-05
AU2011220410B2 (en) 2015-04-02
RS57759B1 (sr) 2018-12-31
PL2538972T3 (pl) 2018-09-28
JP2013521234A (ja) 2013-06-10
NZ602077A (en) 2014-08-29
SI2538972T1 (en) 2018-07-31
CA2791787C (en) 2019-03-26
KR20130036209A (ko) 2013-04-11
EP2538972B1 (en) 2018-04-25
RU2567337C2 (ru) 2015-11-10
ES2676542T3 (es) 2018-07-20
CN102971010A (zh) 2013-03-13

Similar Documents

Publication Publication Date Title
AR080313A1 (es) Composiciones de virus de moquillo canino (cdv) recombinante y sus usos
AR102006A1 (es) Vacunas recombinantes contra el virus de la fiebre aftosa (fmdv) y sus usos
MA34087B1 (fr) Vaccins recombinants contre le virus de la langue bleue et leurs utilisations
MX384422B (es) Vector que expresa conjuntamente vacunas y moléculas coestimuladoras
UY33297A (es) Composiciones farmaceuticas que comprenden un polipéptido que comprende al menos un motivo cxxc y antígenos heterólogos y usos de las mismas
AR089797A1 (es) Vacunas contra clostridum difficile que comprenden toxinas recombinantes
EA201400912A1 (ru) Рекомбинантные поксвирусные векторы, экспрессирующие белки вируса бешенства и ox40, и вакцины, созданные на их основе
PE20151588A1 (es) Vacuna contra el virus del dengue
BR112015023507A2 (pt) vacina estável líquida, e, métodos para vacinar um bovino e para produzir uma vacina estável líquida
PE20150356A1 (es) Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue
MX391908B (es) Vacunas de fmdv vectorizadas con adenovirus recombinantes y usos de las mismas.
CR20150170A (es) Vacunas de inmersión subunidad para peces
MX392857B (es) Nuevos virus de tilapia y sus usos.
CL2017001961A1 (es) Vacuna bivalente contra el virus de gripe porcina
MX2017005687A (es) Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia.
CO7461133A2 (es) Parvovirus 5a porcino, métodos de uso y vacuna
CL2013001877A1 (es) Composicion inmunogenica que comprende un virus de diarrea viral bovina tipo 1b vivo modificado y un portador veterinario aceptable; vacuna que la comprende; y su uso para prevenir, tratar, manejar o aliviar uno o mas sintomas de una enfermedad causada por pestivirus.
BRPI0920622A8 (pt) vacina contra o vírus da doença equina africana
MA37749B1 (fr) Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine
CO2017001614A2 (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9
MX2015013304A (es) Vacunas de nucleoproteina de la influenza.
CL2012000783A1 (es) Proceso para mejorar la eficacia de proteccion metodo para inducir una respuesta inmune contra el virus del dengue que comprende vacunas de dna y virus quimericos 17d; composicion vacunal que comprende vacunas de dna contra los cuatro serotipos del virus dengue y virus quimericos comprendiendo el virus vacunal de fiebre amarilla; plasmido recombinante conteniendo el gen de la proteína e.
BR112014020025A2 (pt) vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas
CL2012003219A1 (es) Parapoxvirus recombinante que comprende un parapoxvirus y adn heterólogo derivado de un virus de la rabia; procedimiento de preparación de dicho parapoxvirus; composicion inmunogénica; uso de la composicion para inducir respuesta inmunitaria contra el virus de la rabia en un animal.
MX2017008087A (es) Virus de la viruela porcina recombinante y vacunas.

Legal Events

Date Code Title Description
FG Grant, registration